Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Introduction
00:00 • 3min
CIGEN's Takeout of CTI BioFarma
02:56 • 5min
Excel and the IPO Market: Will They Open the Floodgates?
07:34 • 2min
The Macro Environment in Biotech
09:55 • 3min
The Shifting Investment Thing on Launches
12:55 • 2min
BioNTech Beats X-Lixis and BioNtech
14:52 • 4min
The EQRX Water Cooler and TGTX
18:32 • 2min
EQRX: A Biotech Company That Has Lost Their Mandatory and Investor Mandate
20:53 • 3min
The CEO's Call Out of a BAML Analyst
23:45 • 2min
The CEO of T.G. Therapeutics Is Calling Out the BAML Analyst
25:24 • 5min
The FDA's Negative Response to the Sorep to Adcom
30:52 • 3min
The Risk of Immunization With AAV
34:08 • 2min
The Difficulty of ARS Approval
36:01 • 2min
The Pros and Cons of Intramuscular Epinephrine
37:35 • 3min
The Upspike of BD Deals Between BioFarma and China BioTec
41:00 • 2min
The FDA Issues CRL for Combination Use of Lead Candidate and Patients With Non-Muscle Invasive Bladder Cancer
42:57 • 2min
The FDA Approves Immunotherapy for Bladder Cancer
44:59 • 3min
The Next 20 Years: A Remarkable Expansion of Genetic Medicine
47:30 • 3min
The Importance of Remote Screening and Diagnosis
50:09 • 2min
The Future of Therapeutics Drug Companies
51:47 • 2min
The Future of Gene Therapy
53:20 • 3min
The Emergence of Branded Drug Sales
56:22 • 3min